Beneficial ownership — 13D / 13G
87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| North Reef Capital Management LP | FFWM First Foundation Inc. | 13G/A | 7.13% | Mar 31, 2026 | 6mo |
| TENOR CAPITAL MANAGEMENT Co., L.P. | VCIC Vine Hill Capital Investment Corp. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| D1 Capital Partners L.P. | CLH Clean Harbors Inc | 13G/A | 2.5% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | PPG Ppg Industries Inc | 13G/A | 4.6% | Mar 31, 2026 | 6mo |
| Dirk Wallinger | YSS York Space Systems Inc. | 13G | 8.6% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | MTSI MACOM Technology Solutions Holdings, Inc. | 13G/A | 6% | Mar 31, 2026 | 6mo |
| Empyrean Capital Partners, LP | KBON Karbon Capital Partners Corp. | 13G/A | 9.18% | Mar 31, 2026 | 6mo |
| BAKER BROS. ADVISORS LP | PRAX Praxis Precision Medicines, Inc. | 13G | 6.3% | Mar 31, 2026 | 6mo |
| Fourthstone LLC | WRIV White River Bancshares Co | 13G/A | 9.75% | Mar 31, 2026 | 6mo |
| MAK Capital Fund LP | AUTL Autolus Therapeutics plc | 13G/A | 12.6% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | OGS ONE Gas, Inc. | 13G/A | 4.2% | Mar 31, 2026 | 6mo |
| RA CAPITAL MANAGEMENT, L.P. | FDMT 4D Molecular Therapeutics, Inc. | 13G/A | 9.9% | Mar 31, 2026 | 6mo |
| ATW Growth Opportunities SPV, LLC | FLD Fold Holdings, Inc. | 13G/A | 3.3% | Mar 31, 2026 | 6mo |
| CVI Investments, Inc. | LAES SEALSQ Corp | 13G/A | 9.9% | Mar 31, 2026 | 6mo |
| MMCAP International Inc. SPC | ASTL Algoma Steel Group Inc. | 13G/A | 12.2% | Mar 31, 2026 | 6mo |
| METEORA CAPITAL, LLC | CEPO Cantor Equity Partners I, Inc. | 13G/A | 14.39% | Mar 31, 2026 | 6mo |
| Vestal Point Capital, LP | TSHA Taysha Gene Therapies, Inc. | 13G/A | 6.3% | Mar 31, 2026 | 6mo |
| BIOTECHNOLOGY VALUE FUND L P | FHTX Foghorn Therapeutics Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Fort Baker Capital Management LP | OACC Oaktree Acquisition Corp. III Life Sciences | 13G | 5.1% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | IMNM Immunome Inc. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| BIOTECHNOLOGY VALUE FUND L P | ELDN Eledon Pharmaceuticals, Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Global X Management CO LLC | LEU Centrus Energy Corp | 13G/A | 6.41% | Mar 31, 2026 | 6mo |
| Euclidean Capital LLC | PMVP PMV Pharmaceuticals, Inc. | 13G/A | 4.9% | Mar 31, 2026 | 6mo |
| Deep Track Capital, LP | CRMD CorMedix Inc. | 13G/A | 7.94% | Mar 31, 2026 | 6mo |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | KIDZ KIDZ AI Inc. | 13G/A | 2.7% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | MEI Methode Electronics Inc | 13G | 5.9% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | OVID Ovid Therapeutics Inc. | 13G/A | 1.3% | Mar 31, 2026 | 6mo |
| Nally Michael | GENB Generate Biomedicines, Inc. | 13G | 5.2% | Mar 31, 2026 | 6mo |
| GCM Investments GP, LLC | CART Maplebear Inc. | 13G/A | 1.7% | Mar 31, 2026 | 6mo |
| Commodore Capital LP | ELVN Enliven Therapeutics, Inc. | 13G/A | 7.7% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | MDWD MediWound Ltd. | 13G | 5.5% | Mar 31, 2026 | 6mo |
| EdgePoint Investment Group Inc. | OR OR Royalties Inc. | 13G/A | 10.38% | Mar 31, 2026 | 6mo |
| Divisadero Street Capital Management, LP | RSI Rush Street Interactive, Inc. | 13G/A | 6.2% | Mar 31, 2026 | 6mo |
| Divesh Makan | NTSK Netskope Inc | 13G/A | 28.7% | Mar 31, 2026 | 6mo |
| RA CAPITAL MANAGEMENT, L.P. | CTNM Contineum Therapeutics, Inc. | 13G/A | 4% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | FTV Fortive Corp | 13G/A | 7.1% | Mar 31, 2026 | 6mo |
| Orbis Investment Management Limited | TBBB Bbb Foods Inc | 13G/A | 9% | Mar 31, 2026 | 6mo |
| 1607 Capital Partners, LLC | EVF Eaton Vance Senior Income Trust | 13G | 5.05% | Mar 31, 2026 | 6mo |
| Two Seas Capital LP | PAVM PAVmed Inc. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| Vestal Point Capital, LP | IMCR Immunocore Holdings plc | 13G | 5.5% | Mar 31, 2026 | 6mo |
| JANUS HENDERSON GROUP PLC | GKOS GLAUKOS Corp | 13G/A | 9.2% | Mar 31, 2026 | 6mo |
| Polar Asset Management Partners Inc. | BCARU D. Boral ARC Acquisition I Corp. | 13G/A | 1.7% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | R Ryder System Inc | 13G/A | 4.4% | Mar 31, 2026 | 6mo |
| Balyasny Asset Management L.P. | CAMP Camp4 Therapeutics Corp | 13G | 5.07% | Mar 31, 2026 | 6mo |
| Orbis Investment Management Limited | QXO QXO, Inc. | 13G/A | 10.2% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | SION Sionna Therapeutics, Inc. | 13G/A | 7.1% | Mar 31, 2026 | 6mo |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | IMAX Imax Corp | 13G/A | 6.8% | Mar 31, 2026 | 6mo |
| COHEN & STEERS, INC. | CTRE CareTrust REIT, Inc. | 13G/A | 5.46% | Mar 31, 2026 | 6mo |
| Woodline Partners LP | QNRX Quoin Pharmaceuticals Ltd. | 13G/A | 4.4% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | RLYB Rallybio Corp | 13G/A | 9.99% | Mar 31, 2026 | 6mo |